✦ LIBER ✦

Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin

✍ Scribed by Michael P. Thomas, Kenneth W. Mahaffey, Karen Chiswell, Marc Cohen, Michael C. Kontos, Elliott M. Antman, James J. Ferguson, Robert M. Califf, Shaun G. Goodman, Richard C. Becker

Book ID: 113080269
Publisher: Springer US
Year: 2012
Tongue: English
Weight: 268 KB
Volume: 34
Category: Article
ISSN: 0929-5305
DOI: 10.1007/s11239-012-0693-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Enoxaparin vs. unfractionated heparin in

Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-Segment elevation acute coronary syndromes managed with an intended early invasive strategy—primary results of the SYNERGY randomized trial

📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Randomized evaluation of the safety and

Randomized evaluation of the safety and efficacy of enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide

✍ S.G. Goodman; D. Fitchett; P.W. Armstrong; M. Tan; A. Langer 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 41 KB

Efficacy and safety of enoxaparin compar

Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial

✍ Harvey D. White; Neal S. Kleiman; Kenneth W. Mahaffey; Yuliya Lokhnygina; Karen 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 333 KB

Randomized evaluation of the efficacy of

Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial

✍ David H. Fitchett; Anatoly Langer; Paul W. Armstrong; Mary Tan; Aurora Mendelsoh 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 142 KB